• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

合成和评估诱导提前终止密码子通读的化合物。

Synthesis and evaluation of compounds that induce readthrough of premature termination codons.

机构信息

Department of Chemistry and Biochemistry, University of California, Los Angeles, 405 Hilgard Ave., Los Angeles, CA 90095, United States.

出版信息

Bioorg Med Chem Lett. 2011 Oct 1;21(19):5842-8. doi: 10.1016/j.bmcl.2011.07.107. Epub 2011 Aug 4.

DOI:10.1016/j.bmcl.2011.07.107
PMID:21873052
Abstract

A structure-activity relationship (SAR) study was carried out to identify novel, small molecular weight compounds which induce readthrough of premature termination codons. In particular, analogs of RTC13, 1, were evaluated. In addition, hypothesizing that these compounds exhibit their activity by binding to the ribosome, we prepared the hybrid analogs 13 containing pyrimidine bases and these also showed good readthrough activity.

摘要

进行了一项结构-活性关系 (SAR) 研究,以确定能诱导提前终止密码子通读的新型小分子化合物。特别是,对 RTC13 的类似物 1 进行了评估。此外,基于这些化合物通过与核糖体结合发挥其活性的假设,我们制备了含有嘧啶碱基的混合类似物 13,它们也表现出良好的通读活性。

相似文献

1
Synthesis and evaluation of compounds that induce readthrough of premature termination codons.合成和评估诱导提前终止密码子通读的化合物。
Bioorg Med Chem Lett. 2011 Oct 1;21(19):5842-8. doi: 10.1016/j.bmcl.2011.07.107. Epub 2011 Aug 4.
2
Different clinical and immunological presentation of ataxia-telangiectasia within the same family.共济失调毛细血管扩张症在同一家族中的不同临床和免疫学表现。
Neuropediatrics. 2008 Feb;39(1):43-5. doi: 10.1055/s-2008-1076736.
3
Use of the comet test to assess DNA damage in children with ataxia-telangiectasia and their relatives.运用彗星试验评估共济失调毛细血管扩张症患儿及其亲属的DNA损伤情况。
J Investig Allergol Clin Immunol. 2008;18(2):137-8.
4
Poly(A)-Binding Protein Regulates the Efficiency of Translation Termination.多聚(A)结合蛋白调控翻译终止的效率。
Cell Rep. 2020 Nov 17;33(7):108399. doi: 10.1016/j.celrep.2020.108399.
5
Functional characterization and targeted correction of ATM mutations identified in Japanese patients with ataxia-telangiectasia.鉴定日本共济失调毛细血管扩张症患者中 ATM 突变的功能特征和靶向校正。
Hum Mutat. 2012 Jan;33(1):198-208. doi: 10.1002/humu.21632. Epub 2011 Nov 9.
6
Translation termination codons in protein synthesis and disease.蛋白质合成与疾病中的翻译终止密码子。
Adv Protein Chem Struct Biol. 2022;132:1-48. doi: 10.1016/bs.apcsb.2022.06.001. Epub 2022 Jul 30.
7
Cytoplasmic ATM protein kinase: an emerging therapeutic target for diabetes, cancer and neuronal degeneration.细胞质 ATM 蛋白激酶:糖尿病、癌症和神经元退行性疾病治疗的新靶点。
Drug Discov Today. 2011 Apr;16(7-8):332-8. doi: 10.1016/j.drudis.2011.02.001. Epub 2011 Feb 15.
8
Sequence specificity of aminoglycoside-induced stop condon readthrough: potential implications for treatment of Duchenne muscular dystrophy.氨基糖苷类诱导的终止密码子通读的序列特异性:对杜氏肌营养不良症治疗的潜在意义。
Ann Neurol. 2000 Aug;48(2):164-9.
9
Nonaminoglycoside compounds induce readthrough of nonsense mutations.非氨基糖苷类化合物可诱导无义突变的通读。
J Exp Med. 2009 Sep 28;206(10):2285-97. doi: 10.1084/jem.20081940. Epub 2009 Sep 21.
10
Transient idling of posttermination ribosomes ready to reinitiate protein synthesis.终止后核糖体的短暂闲置,准备重新启动蛋白质合成。
Biochimie. 2004 Dec;86(12):933-8. doi: 10.1016/j.biochi.2004.08.006.

引用本文的文献

1
Pharmaceuticals Promoting Premature Termination Codon Readthrough: Progress in Development.促进过早终止密码子通读的药物:开发进展。
Biomolecules. 2023 Jun 14;13(6):988. doi: 10.3390/biom13060988.
2
Iron-catalyzed intermolecular cross-dehydrogenative C(sp)-H/C(sp)-H coupling of pyrimidine bearing 4-thiazolidinones with terminal alkynes.铁催化嘧啶并 4-噻唑烷酮与末端炔烃的分子间交叉脱氢 C(sp)-H/C(sp)-H 偶联反应。
Mol Divers. 2022 Dec;26(6):3037-3045. doi: 10.1007/s11030-021-10363-8. Epub 2022 Mar 20.
3
Variable readthrough responsiveness of nonsense mutations in hemophilia A.
血友病 A 中无义突变的可变通读反应性。
Haematologica. 2020 Jan 31;105(2):508-518. doi: 10.3324/haematol.2018.212118. Print 2020.
4
Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons.药物刺激终止密码子通读的治疗用途的进展。
Mol Med. 2018 May 29;24(1):25. doi: 10.1186/s10020-018-0024-7.
5
Clinical potential of ataluren in the treatment of Duchenne muscular dystrophy.阿他芦伦治疗杜氏肌营养不良症的临床潜力。
Degener Neurol Neuromuscul Dis. 2016 May 13;6:37-48. doi: 10.2147/DNND.S71808. eCollection 2016.
6
Efficacy of Postnatal In Vivo Nonsense Suppression Therapy in a Pax6 Mouse Model of Aniridia.产后体内无义抑制疗法在无虹膜Pax6小鼠模型中的疗效
Mol Ther Nucleic Acids. 2017 Jun 16;7:417-428. doi: 10.1016/j.omtn.2017.05.002. Epub 2017 May 8.
7
Nonsense Suppression as an Approach to Treat Lysosomal Storage Diseases.无义抑制作为治疗溶酶体贮积症的一种方法。
Diseases. 2016 Dec;4(4). doi: 10.3390/diseases4040032. Epub 2016 Oct 19.
8
Evaluation of Aminoglycoside and Non-Aminoglycoside Compounds for Stop-Codon Readthrough Therapy in Four Lysosomal Storage Diseases.评估氨基糖苷类和非氨基糖苷类化合物用于四种溶酶体贮积病的终止密码子通读疗法
PLoS One. 2015 Aug 19;10(8):e0135873. doi: 10.1371/journal.pone.0135873. eCollection 2015.
9
High throughput screening in duchenne muscular dystrophy: from drug discovery to functional genomics.杜氏肌营养不良症的高通量筛选:从药物发现到功能基因组学
Biology (Basel). 2014 Nov 14;3(4):752-80. doi: 10.3390/biology3040752.
10
Generating SM(a)RTer compounds for translation termination suppression in A-T and other genetic disorders.生成用于在共济失调毛细血管扩张症及其他遗传性疾病中抑制翻译终止的SM(a)RTer化合物。
Mol Ther. 2013 Sep;21(9):1650-2. doi: 10.1038/mt.2013.177.